Kymera Therapeutics Inc (KYMR) — Strategic Asset Allocation Index
Kymera Therapeutics Inc (KYMR) has a Strategic Asset Allocation Index of 50.0% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $473.06 Million) total $473.06 Million, measured against net assets of $946.26 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Kymera Therapeutics Inc Strategic Asset Allocation Index (2020–2024)
This chart shows how Kymera Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the index stands at 50.0%, representing strategic assets of $473.06 Million against net assets of $946.26 Million USD. Explore Kymera Therapeutics Inc cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Kymera Therapeutics Inc (2020–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Kymera Therapeutics Inc from 2020 to 2024, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see KYMR stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 43.3% | $362.16 Million | $- | $362.16 Million | $835.62 Million | ▲ +27.8 pp |
| 2023 | 15.6% | $61.43 Million | $- | $61.43 Million | $394.97 Million | ▼ -18.2 pp |
| 2022 | 33.8% | $165.66 Million | $13.33 Million | $152.33 Million | $490.15 Million | ▲ +4.0 pp |
| 2021 | 29.8% | $137.07 Million | $11.88 Million | $125.19 Million | $459.64 Million | ▼ -34.7 pp |
| 2020 | 64.5% | $183.22 Million | $20.69 Million | $162.53 Million | $283.89 Million | — |